Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Drug Alcohol Depend ; 140: 8-16, 2014 Jul 01.
Article in English | MEDLINE | ID: mdl-24837581

ABSTRACT

BACKGROUND: Chronic alcohol intake produces multiple neuroadaptive changes, including up- and down-regulation of neuropeptides and receptors. There are widespread projections of relaxin-3 containing neurons to, and abundant relaxin family peptide 3 receptor (RXFP3) expression within, brain regions involved in modulating alcohol intake. Recently we demonstrated the involvement of relaxin-3/RXFP3 signalling in alcohol-seeking in rats; therefore in this study we examined whether relaxin-3 and/or RXFP3 expression were altered by chronic alcohol intake in alcohol-preferring iP rats. METHODS: Expression of relaxin-3 mRNA in the hindbrain nucleus incertus and RXFP3 radioligand binding levels in discrete forebrain regions were investigated following voluntary intake of alcohol or sucrose for 12 weeks, with a 2 day washout, using quantitative in situ hybridisation histochemistry and in vitro receptor autoradiography, respectively, in cohorts of adult, male iP rats. RESULTS: Levels of relaxin-3 mRNA in the hindbrain nucleus incertus were positively correlated with the level of intake of both alcohol (r(12)=0.59, p=0.03) and sucrose (r(7)=0.70, p=0.04) in iP rats. Dense binding of the RXFP3-selective radioligand, [(125)]-R3/I5, was detected in hypothalamic and extrahypothalamic sites, but no significant changes in the density of RXFP3 were observed in the brain regions quantified following chronic sucrose or ethanol intake. CONCLUSIONS: Our findings suggest high endogenous relaxin-3 expression may be associated with higher intake of rewarding substances, rather than its expression being regulated in response to their intake, consistent with an active role for the relaxin-3/RXFP3 system in modulating ingestive and alcohol-related behaviours.


Subject(s)
Alcohol Drinking/genetics , Eating/genetics , RNA, Messenger/biosynthesis , Raphe Nuclei/metabolism , Receptors, G-Protein-Coupled/genetics , Receptors, Peptide/genetics , Alcohol Drinking/psychology , Animals , Drinking/physiology , Male , Rats , Receptors, G-Protein-Coupled/metabolism , Receptors, Peptide/metabolism , Rhombencephalon/drug effects , Rhombencephalon/metabolism , Sucrose/pharmacology
2.
J Neurochem ; 94(6): 1523-34, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16000149

ABSTRACT

Corticotropin-releasing factor is a neuropeptide associated with the integration of physiological and behavioural responses to stress and also in the modulation of affective state and drug reward. The selective, centrally acting corticotropin-releasing factor type 1 receptor antagonist, antalarmin, is a potent anxiolytic and reduces volitional ethanol consumption in Fawn-Hooded rats. The efficacy of antalarmin to reduce ethanol consumption increased with time, suggestive of adaptation to reinforcement processes and goal-directed behaviour. The aim of the present study was to examine the effects of chronic antalarmin treatment on reward-related regions of Fawn-Hooded rat brain. Bi-daily antalarmin treatment (20 mg/kg, i.p.) for 10 days increased tyrosine hydroxylase messenger RNA expression throughout the ventral mesencephalon. Following chronic antalarmin the density of dopaminergic terminals within the basal ganglia and amygdaloid complex were reduced, as was dopamine transporter binding within the striatum. Receptor autoradiography indicated an up-regulation of dopamine D2, but no change in D1, binding in striatum, and Golgi-Cox analysis of striatal medium spiny neurones indicated that chronic antalarmin treatment increased spine density. Thus, chronic antalarmin treatment modulates dopaminergic pathways and implies that chronic treatment with drugs of this class may ultimately alter postsynaptic signaling mechanisms within the basal ganglia.


Subject(s)
Brain/drug effects , Corticotropin-Releasing Hormone/metabolism , Dopamine/metabolism , Pyrimidines/pharmacology , Pyrroles/pharmacology , Receptors, Corticotropin-Releasing Hormone/antagonists & inhibitors , Reward , Amygdala/drug effects , Amygdala/metabolism , Animals , Basal Ganglia/drug effects , Basal Ganglia/metabolism , Brain/metabolism , Brain/physiopathology , Dendritic Spines/drug effects , Dendritic Spines/metabolism , Drug Administration Schedule , Male , Mesencephalon/drug effects , Mesencephalon/metabolism , Neural Pathways/drug effects , Neural Pathways/metabolism , Presynaptic Terminals/drug effects , Presynaptic Terminals/metabolism , RNA, Messenger/drug effects , RNA, Messenger/metabolism , Rats , Receptors, Corticotropin-Releasing Hormone/metabolism , Receptors, Dopamine D1/drug effects , Receptors, Dopamine D1/metabolism , Reinforcement, Psychology , Synaptic Transmission/drug effects , Synaptic Transmission/physiology , Tyrosine 3-Monooxygenase/genetics , Up-Regulation/drug effects , Up-Regulation/physiology
3.
J Neurochem ; 86(2): 329-43, 2003 Jul.
Article in English | MEDLINE | ID: mdl-12871574

ABSTRACT

Following partial substantia nigra lesions, remaining dopaminergic neurones sprout, returning terminal density in the dorsal striatum to normal by 16 weeks. This suggests regeneration and maintenance of terminal density is regulated to release appropriate levels of dopamine. This study examined the structure and function of these reinnervated terminals, defining characteristics of dopamine uptake and release, density and affinity of the dopamine transporter (DAT) and ultrastructural morphology of dopamine terminals in the reinnervated dorsal striatum. Finally, rotational behaviour of animals in response to amphetamine was examined 4 and 16 weeks after substantia nigra pars compacta (SNpc) lesions. Dopamine transport was markedly reduced 16 weeks after lesioning along with reduced density and affinity of DAT. Rate of dopamine release and peak concentration, measured electrochemically, was similar in lesioned and control animals, while clearance was prolonged after lesioning. Ultrastructurally, terminals after lesioning were morphologically distinct, having increased bouton size, vesicle number and mitochondria, and more proximal contacts on post-synaptic cells. After 4 weeks, tendency to rotate in response to amphetamine was proportional to lesion size. By 16 weeks, rotational behaviour returned to near normal in animals where lesions were less than 70%, although some animals demonstrated unusual rotational patterns at the beginning and end of the amphetamine effect. Together, these changes indicate that sprouted terminals are well compensated for dopamine release but that transport mechanisms are functionally impaired. We discuss these results in terms of implications for dyskinesia and other behavioural states.


Subject(s)
Corpus Striatum/physiology , Dopamine/metabolism , Membrane Glycoproteins , Nerve Regeneration/physiology , Nerve Tissue Proteins , Presynaptic Terminals/physiology , Presynaptic Terminals/ultrastructure , Substantia Nigra/physiology , Amphetamine/pharmacology , Animals , Behavior, Animal/drug effects , Binding, Competitive/drug effects , Biological Transport/drug effects , Cell Count , Corpus Striatum/ultrastructure , Dopamine Agonists/pharmacology , Dopamine Plasma Membrane Transport Proteins , Dopamine Uptake Inhibitors/pharmacokinetics , Dopamine Uptake Inhibitors/pharmacology , Electrochemistry , Male , Mazindol/pharmacokinetics , Membrane Transport Proteins/metabolism , Nerve Regeneration/drug effects , Oxidopamine/pharmacology , Quinpirole/pharmacology , Rats , Rats, Wistar , Substantia Nigra/drug effects , Synaptosomes/chemistry , Synaptosomes/drug effects , Synaptosomes/metabolism
4.
Neuroscience ; 113(4): 809-23, 2002.
Article in English | MEDLINE | ID: mdl-12182888

ABSTRACT

The present study employed standard peroxidase immunohistochemistry to map the distribution of P2Y(1) receptors in the rat brainstem and nodose ganglia and characterised the binding profile of [alpha(33)P]dATP. Binding of [alpha(33)P]dATP was fully displaceable by adenosine 5'-triphosphate (ATP), and was found on both human and rat nodose ganglia, and throughout the rat brainstem, including the nucleus tractus solitarius and ventrolateral medulla. [Alpha(33)P]dATP binding in the human nodose ganglia was significantly displaced by both 2-methylthio ATP and alpha,beta-methylene ATP, but not by uridine 5'-triphosphate, pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid, 8,8'-(carbonylbis(imino-4,1-phenylenecarbonylimino-4,1-phenylenecarbonylimino))bis(1,3,5-naphtalenetrisulfonic) acid (NF279) or N-ethylcarboxamidoadenosine. [Alpha(33)P]dATP binding in the rat nodose ganglia and brainstem was significantly displaced by only 2-methylthio ATP, suggesting that [alpha(33)P]dATP is binding to P2Y receptors in the rat. Binding of [alpha(33)P]dATP was also significantly displaced by alpha,beta-methylene adenosine 5'-diphosphate, suggesting a component of the binding is to endogenous ecto-5'-nucleotidase, however, almost all binding could be displaced by a combination of receptor agonists (2-methylthio ATP, uridine 5'-triphosphate and alpha,beta-methylene ATP), suggesting preferential binding to receptors. Immunoreactivity to P2Y(1) receptor (P2Y(1)-IR) exhibited similar distribution patterns to [alpha(33)P]dATP binding, with a clear topographic profile. Particularly dense P2Y(1)-IR labeling was evident in cells and fibres of the dorsal vagal complex. Immunolabeling was also present in the dorsal motor nucleus of the vagus and nucleus ambiguus, indicating the possibility of P2Y(1) receptors on vagal efferents. Unilateral vagal ligation was also performed to examine the transport of P2Y(1) receptor, using both immunohistochemistry and [alpha(33)P]dATP autoradiography. Accumulations of both P2Y(1)-IR and [alpha(33)P]dATP binding were apparent adjacent to both ligatures, suggesting bi-directional transport of P2Y(1) receptors along the rat vagus nerve. This current study represents the first description of P2Y(1) receptor distribution within the rodent brainstem and nodose ganglion and also characterises [alpha(33)P]dATP binding to P2Y receptors.


Subject(s)
Brain Stem/metabolism , Deoxyadenine Nucleotides/metabolism , Nodose Ganglion/metabolism , Receptors, Purinergic P2/metabolism , Adolescent , Adult , Aged , Animals , Autoradiography/methods , Autoradiography/statistics & numerical data , Brain Stem/chemistry , Humans , Immunohistochemistry , Male , Middle Aged , Nodose Ganglion/chemistry , Phosphorus Radioisotopes/metabolism , Rats , Rats, Inbred WKY , Receptors, Purinergic P2/analysis , Receptors, Purinergic P2Y1
5.
Br J Pharmacol ; 136(6): 896-904, 2002 Jul.
Article in English | MEDLINE | ID: mdl-12110614

ABSTRACT

1. Novel analogues of antisauvagine-30 (aSvg-30), a selective antagonist for CRF(2) receptors, have been synthesized and characterized in vitro and in vivo. 2. The analogues were tested for their ability to compete for [(125)I-Tyr(0)]Svg binding and to inhibit Svg-stimulated adenylate cyclase activity in human embryonic kidney (HEK) 293 cells, permanently transfected with cDNA coding for the human CRF(1) (hCRF(1)), hCRF(2alpha) and hCRF(2beta) receptor. One analogue [D-Phe(11), His(12), Nle(17)]Svg(11-40), named K41498, showed high affinity binding to hCRF(2alpha) (K(i)=0.66+/-0.03 nM) and hCRF(2beta) (K(i)=0.62+/-0.01 nM) but not the hCRF(1) receptor (k(i)=425+50 nM) and decreased Svg-stimulated cAMP accumulation in hCRF(2) expressing cells. In conscious Wistar-Kyoto rats, K41498 (1.84 microg, i.v.) antagonized the hypotensive response to systemic urocortin (1.4 microg, i.v.), but did not block the pressor response to centrally administered urocortin (2.35 microg, i.c.v.). 3. K41498 was subsequently radio-iodinated, and in autoradiographic studies, specific (sensitive to rat urocortin, astressin and aSvg30, but insensitive to antalarmin) binding of (125)I-K41498 (100 pM) was detected in the heart and in selected brain regions including the nucleus tractus solitarius (NTS), spinal trigeminal nucleus, lateral septum and around the anterior and middle cerebral arteries. 4. Following unilateral nodose ganglionectomy, binding of (125)I-K41498 was reduced by 65% in the ipsilateral NTS, indicative of presynaptic CRF(2) receptors on vagal afferent terminals. 5. These data demonstrate that K41498 is a useful tool to study native CRF(2) receptors in the brain and periphery.


Subject(s)
Cardiovascular Agents/pharmacology , Cardiovascular Agents/pharmacokinetics , Peptide Fragments/metabolism , Receptors, Corticotropin-Releasing Hormone/metabolism , Receptors, Presynaptic/metabolism , Amino Acid Sequence , Amphibian Proteins , Analysis of Variance , Animals , Autoradiography , Binding Sites , Binding, Competitive , Blood Pressure/drug effects , Brain/metabolism , Cell Line , Cyclic AMP/biosynthesis , Humans , In Vitro Techniques , Injections, Intravenous , Male , Molecular Sequence Data , Myocardium/metabolism , Nodose Ganglion/metabolism , Peptide Fragments/pharmacology , Peptide Hormones , Radioligand Assay , Rats , Rats, Inbred WKY , Receptors, Corticotropin-Releasing Hormone/antagonists & inhibitors , Receptors, Presynaptic/antagonists & inhibitors
6.
Neuroreport ; 12(8): 1629-33, 2001 Jun 13.
Article in English | MEDLINE | ID: mdl-11409729

ABSTRACT

Hyperthermia during or after stroke is known to worsen neuronal damage. Paradoxically, when hyperthermia precedes stroke, it can protect against a subsequent ischemic insult. Other stressors including restraint also have a similar pre-conditioning effect. In the present study, we report the unanticipated finding that conscious rats, restrained for the purpose of intravenous infusion, had markedly reduced neuronal and functional deficits after middle cerebral artery occlusion compared with unrestrained rats. Restrained rats had significantly higher body temperature prior to stroke than unrestrained rats. The findings suggest restraint leading to mild hyperthermia may be sufficient to induce adaptive processes which protect against subsequent ischemia.


Subject(s)
Brain Ischemia/physiopathology , Hyperthermia, Induced , Adaptation, Physiological , Animals , Body Temperature , Brain Ischemia/pathology , Cerebral Cortex/pathology , Cerebral Infarction/chemically induced , Cerebral Infarction/pathology , Cerebral Infarction/physiopathology , Corpus Striatum/pathology , Endothelin-1 , Male , Motor Activity , Rats , Rats, Wistar , Restraint, Physical , Stroke/chemically induced , Stroke/pathology
7.
Clin Exp Pharmacol Physiol ; 10(2): 171-5, 1983.
Article in English | MEDLINE | ID: mdl-6409479

ABSTRACT

Indomethacin (2.8 mumol/l) did not consistently affect basal tone of sheep coronary artery strips, while a ten-fold higher concentration increased tension in 50% of the preparations tested. When acetylcholine was used as a spasmogen, oscillations in induced tone and relaxations produced by arachidonic acid (6.6 mumol/l) were abolished by indomethacin, 2.8 mumol/l and 7 mumol/l, respectively. Prostacyclin (PGI2) and prostaglandin E1 decreased and PGE2 increased arterial tension while PGF2 alpha was inactive. Responses to PGI2 were reduced by indomethacin (28 mumol/l) but not by indomethacin (2.8 mumol/l). It is suggested that sheep isolated coronary arteries synthesize and release prostacyclin in the presence of acetylcholine and arachidonic acid and that such synthesis can be inhibited by indomethacin.


Subject(s)
Arachidonic Acids/pharmacology , Coronary Vessels/drug effects , Indomethacin/pharmacology , Acetylcholine/pharmacology , Animals , Arachidonic Acid , Dinoprost , Dinoprostone , Drug Interactions , Epoprostenol/pharmacology , In Vitro Techniques , Prostaglandins/pharmacology , Prostaglandins E/pharmacology , Prostaglandins F/pharmacology , Sheep , Vasodilation/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...